On this page
Geroderma osteodysplastica
This condition causes loose, wrinkled skin, particularly on the hands and feet, alongside bone abnormalities such as reduced bone density. It is present from birth and affects individuals globally.
Available at Jeen Health
Clinical tests that include this
Overview
Geroderma osteodysplastica is a very rare genetic disorder that primarily impacts the body's connective tissues. Connective tissues provide support, bind other tissues together, and help to maintain the shape of organs. In this condition, the changes in connective tissue lead to noticeable skin features and skeletal issues [PMID:19114881]. Typically, individuals are diagnosed in infancy or early childhood due to these distinctive characteristics. The condition is sometimes referred to as 'wrinkly skin syndrome' because of its effect on the skin's elasticity.
Symptoms & clinical features
Individuals with Geroderma osteodysplastica often present with loose, wrinkled skin, most prominently on the hands, feet, and abdomen, giving an appearance that may seem prematurely aged. The skin can also appear thin and fragile. Beyond the skin, individuals may experience a range of skeletal abnormalities. These can include reduced bone density, which might lead to an increased risk of bone fractures. Joint hypermobility, where joints can move beyond their normal range, is also a reported feature [PMID:19114881].
Other potential features can include a distinctive facial appearance, with a broad nasal bridge and a small chin. Some individuals might also experience developmental delay, though the severity can vary greatly between affected individuals. Eye abnormalities and dental issues have also been observed in some cases.
Video: Genetics 101
Affected organs
The primary organs and systems affected in Geroderma osteodysplastica are the skin and the skeletal system. The skin, a major connective tissue organ, shows reduced elasticity and increased wrinkling. The skeletal system is affected by bone demineralisation, meaning the bones may have lower than usual density, potentially increasing their fragility. Joints are also commonly affected, exhibiting increased flexibility.
Risks & severity
The severity of Geroderma osteodysplastica can vary, even within the same family. While some individuals may experience milder skin and bone changes, others might have more pronounced skeletal issues or developmental differences. The reduced bone density can contribute to a higher risk of fractures throughout life. The looseness of the skin does not typically pose significant health problems beyond its appearance.
Since this is a rare condition, the exact prevalence is not well established. The age of onset is generally at birth or during early childhood, as many of the characteristic features are noticeable from a young age or develop soon after birth. The condition is chronic, meaning it is long-lasting, and management focuses on addressing the specific symptoms experienced by each individual.
Genetic causes
Geroderma osteodysplastica is caused by genetic changes (variants) in the GORAB gene [PMID:24147714]. The GORAB gene provides instructions for making a protein called golgin, RAB6 interacting, which plays a role in the function of the Golgi apparatus. The Golgi apparatus is a cellular organelle responsible for modifying, sorting, and packaging proteins and lipids for secretion or delivery to other organelles.
When there are pathogenic variants in the GORAB gene, the golgin, RAB6 interacting protein may not function correctly. This disruption is thought to impair processes within the cell that are critical for the formation and maintenance of healthy connective tissues, leading to the characteristic skin and skeletal features observed in Geroderma osteodysplastica. In particular, this protein is known to be involved in collagen processing, and collagen is a key component of connective tissue [PMID:24147714].
- GORAB golgin, RAB6 interacting
Inheritance pattern
Geroderma osteodysplastica is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the altered GORAB gene - one from each parent - to develop the condition. If a person inherits only one copy of the altered gene, they are considered a 'carrier' and typically do not show symptoms of the condition. Carriers have a 50% chance of passing on the altered gene to each of their children.
When two carriers have children together, there is a 25% chance with each pregnancy that their child will inherit two copies of the altered gene and therefore develop Geroderma osteodysplastica. There is also a 50% chance the child will be a carrier, and a 25% chance the child will inherit two normal copies of the gene.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of Geroderma osteodysplastica is usually suspected based on the characteristic clinical features, such as the distinctive skin appearance and skeletal abnormalities, often identified in infancy or early childhood. A definitive diagnosis is confirmed through genetic testing, which identifies pathogenic variants in the GORAB gene.
In the UK, if Geroderma osteodysplastica is suspected, a healthcare professional, often a paediatrician or clinical geneticist, can refer an individual for genetic testing. This testing typically falls under the NHS National Genomic Test Directory, and can be requested using the appropriate R-codes. Clinical geneticists and genetic counsellors can provide support and information during the diagnostic process and help families understand the implications of a diagnosis.
Management & lifestyle
Due to the rarity of Geroderma osteodysplastica, there isn't a single standard treatment, and management typically focuses on addressing the individual symptoms and features. This 'symptomatic and supportive' approach aims to improve quality of life. For skeletal issues, such as reduced bone density, regular monitoring and sometimes specific treatments may be considered by orthopaedic specialists or endocrinologists.
Joint hypermobility may benefit from physiotherapy to strengthen surrounding muscles and improve stability. For developmental delays, early intervention programmes, including educational support and therapies, may be beneficial. Regular follow-up with a paediatrician and other specialists like dermatologists, orthopaedists, and geneticists is important to monitor health and address any emerging concerns within the NHS care pathway. Genetic counselling is also available to families to explain the condition and discuss inheritance patterns.
UK care pathway
In the UK, individuals suspected of having a rare genetic condition like Geroderma osteodysplastica would typically enter the NHS Genomic Medicine Service (GMS) pathway. Referral is usually made by a general practitioner or specialist, such as a paediatrician, to a Regional Clinical Genetics Centre. Clinical geneticists can assess symptoms, provide a provisional diagnosis, and arrange for genomic testing as per the NHS National Genomic Test Directory (using relevant R-codes). Genetic counsellors within these services play a vital role in supporting individuals and families through diagnosis, explaining inheritance patterns, and discussing implications for family members.
Frequently asked questions
Is Geroderma osteodysplastica a progressive condition?
Geroderma osteodysplastica is present from birth, and its core features, such as loose skin and bone density issues, are generally long-lasting. While the specific impact can vary, the condition itself is chronic rather than worsening progressively over time in all aspects.
Can carriers of the GORAB gene variant experience symptoms?
No, individuals who carry only one copy of the altered GORAB gene are typically asymptomatic. They do not develop Geroderma osteodysplastica themselves but can pass the gene variant to their children.
What kind of support is available for families affected by this condition?
Families in the UK can access support through their local NHS Clinical Genetics Centre, which provides genetic counselling and connects them with relevant medical specialists. Patient support groups for rare conditions can also offer valuable resources and community.
Are there any specific lifestyle recommendations for managing the condition?
While no specific diet or lifestyle will cure Geroderma osteodysplastica, maintaining a healthy, balanced diet and engaging in appropriate, safe exercise can support overall bone health and muscle strength. Any specific recommendations should come from a healthcare professional.
Will my child definitely have developmental delay if they have Geroderma osteodysplastica?
No, developmental delay is a noted feature in some individuals with Geroderma osteodysplastica, but it is not seen in all cases and can vary in severity. Regular developmental assessments can help monitor a child's progress.
References
- Saad C, Aoun C, Iskandar C. Geroderma Osteodysplastica With Concomitant Transposition of Great Vessels: A Case Report and Literature Review. Case reports in genetics. 2024. PMID: 39619733
- Sommer A. Photo essay--geroderma osteodysplastica. American journal of medical genetics. Part C, Seminars in medical genetics. 2007. PMID: 17640054
- Almutairi W, Alibrahim A, Alrashed F. Geroderma Osteodysplastica in Two Patients: Clinical, Genetic, and Management Insights. Journal of medical cases. 2026. PMID: 42490798
- Slaiby N, Asmar R, Asmar C. Geroderma Osteodysplastica: A Narrative Review of Its Genetic Basis, Clinical Features, and Management. Clinical genetics. 2026. PMID: 41457302
- Hunter AG. Is geroderma osteodysplastica underdiagnosed? Journal of medical genetics. 1988. PMID: 3236370
- Jukkola A, Kauppila S, Risteli L. New lethal disease involving type I and III collagen defect resembling geroderma osteodysplastica, De Barsy syndrome, and Ehlers-Danlos syndrome IV. Journal of medical genetics. 1998. PMID: 9643297
- Kariminejad A, Afroozan F, Bozorgmehr B. Discriminative Features in Three Autosomal Recessive Cutis Laxa Syndromes: Cutis Laxa IIA, Cutis Laxa IIB, and Geroderma Osteoplastica. International journal of molecular sciences. 2017. PMID: 28294978
- Takeda R, Takagi M, Shinohara H. Novel compound heterozygous mutations identified by whole exome sequencing in a Japanese patient with geroderma osteodysplastica. European journal of medical genetics. 2017. PMID: 28807865